Background/Aims Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.
Methods We analyzed data from CHB patients for whom initiated NA treatment from 30 centers. We balanced patient characteristics with and without metabolic disease (diabetes, obesity, dyslipidemia, and hypertension) via propensity-score matching (PSM) to evaluate adverse outcomes.
Results The study included 4,500 patients. PSM yielded 909 pairs of patients with balanced characteristics. When stratified by the number of metabolic diseases, only patients with ≥2 metabolic diseases had an increased cumulative incidence of cirrhosis and overall death. However, when stratified by the presence of diabetes (regardless of the presence or number of other metabolic diseases), patients with diabetes (versus those without) had a significantly higher cumulative incidence of all outcomes: cirrhosis (P=0.009), hepatocellular carcinoma (HCC, P=0.023), and overall, liver-related, and non-liver-related death (P<0.001, P=0.026 and P<0.001, respectively). Having ≥2 metabolic diseases was associated with cirrhosis, overall death, and non-liver-related death but not HCC or liver-related death, while diabetes was significantly associated with a higher risk of all outcomes: cirrhosis (hazard ratio [HR]=3.75, P=0.004), HCC (HR=2.02, P=0.020), and overall, liver-related, and non-liver-related death (HR=2.53, P<0.001; HR=2.65, P=0.016; HR=2.38, P<0.001).
Conclusions Having two or more metabolic diseases was associated with a higher risk of cirrhosis, overall death, and non-liver-related death, but having diabetes as a single metabolic disease was significantly associated with all adverse outcomes including cirrhosis, HCC, and overall, liver-related, and non-liver-related death.
Citations
Citations to this article as recorded by
Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2025;[Epub] CrossRef
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang Emerging Microbes & Infections.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Multifunctional Metal Composite Hydrogels for Diabetic Wound Therapy Shengnan Zhang, Hui Gao, Kevin H. Mayo, Jingang Mo, Le Deng Gels.2025; 11(12): 960. CrossRef
Non-alcoholic fatty liver disease (NAFLD) is accepted as a counterpart to alcohol-related liver disease because it is defined as hepatic steatosis without excessive use of alcohol. However, the definition of moderate alcohol consumption, as well as whether moderate alcohol consumption is beneficial or detrimental, remains controversial. In this review, the findings of clinical studies to date with high-quality evidence regarding the effects of moderate alcohol consumption in NAFLD patients were compared and summarized.
Citations
Citations to this article as recorded by
Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung Journal of Korean Medical Science.2026;[Epub] CrossRef
Effects of moderate beer consumption on immunity and the gut microbiome in immunosuppressed mice Shumin HU, Hua YIN, Xiaxia LI, Minghao FAN, Huajun LI Bioscience of Microbiota, Food and Health.2025; 44(1): 32. CrossRef
Changes in drinking levels and metabolic dysfunction-associated steatotic liver disease: a longitudinal study from the China multi-ethnic cohort study Ning Zhang, Jingzhong Li, Xiaofen Xie, Yifan Hu, Hongxiang Chen, Yuan Zhang, Yujie Liu, Xingren Zhu, Hao Xu, Zhenghong Wang, Kangzhuo Baima, Xuehui Zhang, Zixiu Qin, Zhimiao Yu, Xiong Xiao, Xing Zhao BMC Public Health.2025;[Epub] CrossRef
Alcohol-associated liver disease: Natural history, management and novel targeted therapies Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós-Ginès, Ana Clemente-Sánchez, Hugo López-Pelayo, Ramón Bataller Clinical and Molecular Hepatology.2025; 31(Suppl): S112. CrossRef
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo International Journal of Molecular Sciences.2025; 26(4): 1778. CrossRef
Association between alcohol consumption and hepatic fibrosis in Chinese adult males with metabolic dysfunction-associated steatotic liver disease Mao Li, Bin Yu, Xiaoli Zhang, Jia Pan, Lei Tang, Yi Zhang, Ruixin Wang, Honglian Zeng, Shujuan Yang Frontiers in Medicine.2025;[Epub] CrossRef
Metabolic Impact of Alcohol Consumption in MASLD: Understanding MetALD and Beyond Eva Juárez-Hernández, Montserrat Berrospe-Alfaro, Misael Uribe, Iván López-Mendez Journal of Clinical and Experimental Hepatology.2025; 15(6): 103114. CrossRef
Alcohol-Induced Oxidative Stress and Gut–Liver–Brain Crosstalk: Expanding the Paradigm from ALD to MetALD Jeong-Yoon Lee, Young-Min Jee, Keungmo Yang, Tom Ryu Antioxidants.2025; 14(10): 1196. CrossRef
Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung Annals of Liver Transplantation.2025; 5(2): 107. CrossRef
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Liver Cancer.2024; 13(5): 561. CrossRef
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599. CrossRef
Alcohol consumption and its association with cancer, cardiovascular, liver and brain diseases: a systematic review of Mendelian randomization studies Naouras Bouajila, Cloé Domenighetti, Henri-Jean Aubin, Mickael Naassila Frontiers in Epidemiology.2024;[Epub] CrossRef
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease Ji-Won Park, Ki Tae Suk Clinical and Molecular Hepatology.2023; 29(2): 408. CrossRef
Oxidative balance score is inversely associated with the incidence of non-alcoholic fatty liver disease A-Ra Cho, Yu-Jin Kwon, Jun-Hyuk Lee Clinical Nutrition.2023; 42(8): 1292. CrossRef
Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank Yu Jia, Dongze Li, Yi You, Jing Yu, Wenli Jiang, Yi Liu, Rui Zeng, Zhi Wan, Yi Lei, Xiaoyang Liao BMC Medicine.2023;[Epub] CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim
Clin Mol Hepatol 2020;26(3):328-339. Published online May 28, 2020
Background/Aims Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients.
Methods Consecutive HCC patients who received regorafenib or nivolumab after failure of sorafenib treatment were included. Primary endpoint was overall survival (OS) and secondary endpoints were time to progression, tumor response rate, and adverse events. Inverse probability of treatment weighting (IPTW) using the propensity score was conducted to reduce treatment selection bias.
Results Among 150 study patients, 102 patients received regorafenib and 48 patients received nivolumab. Median OS was 6.9 (95% confidence interval [CI], 3.0–10.8) months for regorafenib and 5.9 (95% CI, 3.7–8.1) months for nivolumab (P=0.77 by log-rank test). In multivariable analysis, nivolumab was associated with prolonged OS (vs. regorafenib: adjusted hazard ratio [aHR], 0.54; 95% CI, 0.30–0.96; P=0.04). Time to progression was not significantly different between groups (nivolumab vs. regorafenib: aHR, 0.82; 95% CI, 0.51–1.30; P=0.48). HRs were maintained after IPTW. Objective response rates were 5.9% and 16.7% in patients treated with regorafenib and nivolumab, respectively (P=0.04).
Conclusions After sorafenib failure, the use of nivolumab may be associated with improved OS and better objective response rate as compared to using regorafenib.
Citations
Citations to this article as recorded by
Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis Yunzhi Shen, Yu Bai Medicine.2025; 104(4): e41356. CrossRef
Efficacy and Safety of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Muhammad A.B. Naeem, Muhammad R. Paracha, Ahmad Noor, Muhammad H.A. Khalid, Hafiza K. Shahid, Maaz Khan, Moeaza R. Rizvi, Javeeria Arshad, Talha Abbas, Azeem Saeed, Hamza Ashraf, Minahil Ali, Mishal Asif, Aanusha Ghouri American Journal of Clinical Oncology.2025;[Epub] CrossRef
Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma Kazuto Tajiri, Nozomu Muraishi, Aiko Murayama, Yuka Hayashi, Ichiro Yasuda Hepatology Research.2024; 54(4): 403. CrossRef
Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review Ruyi Zhang, Fang Wang, Zhiyu You, Dongyang Deng, Jiangyan He, Wentao Yan, Jian Quan, Jing Wang, Shujuan Yan Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim Yonsei Medical Journal.2024; 65(7): 371. CrossRef
Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma Faisal M. Sanai, Hassan O. Odah, Kanan Alshammari, Adnan Alzanbagi, Murooj Alsubhi, Hani Tamim, Ashwaq Alolayan, Ahmed Alshehri, Saleh A. Alqahtani Cancers.2024; 16(12): 2196. CrossRef
The interdisciplinary approach to investigate bona fide agent(s) in flavonoids or alkaloids in treating HCC Ki-Kwang Oh, Sang-Jun Yoon, Seol Hee Song, Jeong Ha Park, Jeong Su Kim, Min Ju Kim, Goo-Hyun Kwon, Dong Joon Kim, Ki-Tae Suk Artificial Cells, Nanomedicine, and Biotechnology.2024; 52(1): 500. CrossRef
Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis Yuwei Liu, Jiahui Pan, Fangbo Gao, Wentao Xu, Hongyu Li, Xingshun Qi Advances in Therapy.2023; 40(2): 521. CrossRef
Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Cheng-Long Han, Guang-Xiao Meng, Jun-Shuai Xue, Zhao-Ru Dong, Yu-Chuan Yan, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang, Tao Li International Immunopharmacology.2023; 114: 109519. CrossRef
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim European Journal of Gastroenterology & Hepatology.2023; 35(2): 191. CrossRef
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma Carmelo Laface, Girolamo Ranieri, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Michele Ammendola, Marigia Laterza, Gerardo Cazzato, Riccardo Memeo, Giovanni Mastrandrea, Marco Lioce, Palma Fedele Cancers.2023; 15(3): 654. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis Ding XIONG, Kui ZHANG, Mingqing XU Panminerva Medica.2023;[Epub] CrossRef
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook Yinjie Fan, Hang Xue, Huachuan Zheng Journal of Hepatocellular Carcinoma.2022; Volume 9: 233. CrossRef
Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon Journal for ImmunoTherapy of Cancer.2022; 10(5): e003618. CrossRef
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma Kuo-Wei Huang, Pei-Chang Lee, Yee Chao, Chien-Wei Su, I-Cheng Lee, Keng-Hsin Lan, Chi-Jen Chu, Yi-Ping Hung, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go Pil Soo Sung, Isaac Kise Lee, Pu Reun Roh, Min Woo Kang, Jaegyoon Ahn, Seung Kew Yoon Frontiers in Oncology.2022;[Epub] CrossRef
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea Min Jin Lee, Sung Won Chang, Ji Hoon Kim, Young-Sun Lee, Sung Bum Cho, Yeon Seok Seo, Hyung Joon Yim, Sang Youn Hwang, Hyun Woong Lee, Young Chang, Jae Young Jang Investigational New Drugs.2021; 39(1): 260. CrossRef
Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways Bingjian Wen, Chengcheng Zhang, Jingwen Zhou, Zhengyan Zhang, Qishi Che, Hua Cao, Yan Bai, Jiao Guo, Zhengquan Su Pharmacology & Therapeutics.2021; 222: 107752. CrossRef
Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, In‐Soo Shin, Chai Hong Rim Journal of Hepato-Biliary-Pancreatic Sciences.2021; 28(12): 1031. CrossRef
The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Shukang He, Weichao Jiang, Kai Fan, Xiaobei Wang Frontiers in Oncology.2021;[Epub] CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
Evolving therapeutic strategies for advanced hepatocellular carcinoma Ammar Qureshi, Miguel Michel, Jaren Lerner, Constantin A. Dasanu Expert Opinion on Pharmacotherapy.2021; 22(18): 2495. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang Frontiers in Oncology.2021;[Epub] CrossRef
Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro Translational Oncology.2021; 14(9): 101158. CrossRef
Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment Bo Hyun Kim, Joong-Won Park Journal of Liver Cancer.2021; 21(2): 124. CrossRef
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki International Journal of Molecular Sciences.2021; 22(11): 5801. CrossRef
Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis Huilin Xu, Dedong Cao, Yongfa Zheng, Dingjie Zhou, Xin Chen, Jinju Lei, Wei Ge, Ximing Xu International Immunopharmacology.2021; 100: 108135. CrossRef
Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study Jaejun Lee, Ji-Won Han, Pil-Soo Sung, Soon-Kyu Lee, Hyun Yang, Hee-Chul Nam, Sun-Hong Yoo, Hae-Lim Lee, Hee-Yeon Kim, Sung-Won Lee, Jung-Hyun Kwon, Jeong-Won Jang, Chang-Wook Kim, Soon-Woo Nam, Jung-Suk Oh, Ho-Jong Chun, Si-Hyun Bae, Jong-Young Choi, Seun Journal of Clinical Medicine.2021; 10(18): 4045. CrossRef
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma Sojung Han, Do Young Kim Clinical and Molecular Hepatology.2020; 26(3): 305. CrossRef
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Mohamed A. Abd El Aziz, Antonio Facciorusso, Tarek Nayfeh, Samer Saadi, Mohamed Elnaggar, Christian Cotsoglou, Rodolfo Sacco Vaccines.2020; 8(4): 616. CrossRef
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is a “hot potato” for pharmaceutical companies. Many clinical trials are underway to develop a first-in-class drug to treat NAFLD. However, there are several challenging issues regarding the diagnosis of NAFLD. Currently, liver biopsy is the gold standard method for the diagnosis of NAFLD and steatohepatitis. Ideally, globally recognized standards for histological diagnosis and methods to optimize observer agreement on biopsy interpretation should be developed. Liver biopsy is the best method rather than a perfect one. Recently, multi-parametric magnetic resonance imagery can estimate the amount of intrahepatic fat successfully and is widely used in clinical trials. But no diagnostic method can discriminate between steatohepatitis and simple steatosis. The other unresolved issue in regard to NAFLD is the absence of satisfactory treatment options. Vitamin E and obeticholic acid have shown protective effects in randomized controlled trials, but this drug has not been approved for use in Korea. This study will provide a description of diagnostic methods and treatments that are currently recommended for NAFLD.
Citations
Citations to this article as recorded by
Chaihu-Shugan-San for patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis Xiangke Qu, Jianrong Sun, Yue Shen, Jia Dong, Xiaofa Li, Yanchun Ma, Jinhui Sun Medicine.2025; 104(18): e42303. CrossRef
Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests Huiyul Park, Eileen L. Yoon, Mimi Kim, Ji-hyeon Park, Ramsey Cheung, Jeong-Yeon Cho, Hye-Lin Kim, Dae Won Jun Scientific Reports.2025;[Epub] CrossRef
The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis Qiong Lv, Huashan Zhao Annals of Medicine.2024;[Epub] CrossRef
Cost‐effectiveness study of FIB‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at‐risk population Huiyul Park, Eileen L. Yoon, Mimi Kim, Sun‐Hong Kwon, Donghee Kim, Ramsey Cheung, Hye‐Lin Kim, Dae Won Jun Liver International.2024; 44(4): 944. CrossRef
Heating Induced Nanoparticle Migration and Enhanced Delivery in Tumor Treatment Using Nanotechnology Qimei Gu, Liang Zhu Bioengineering.2024; 11(9): 900. CrossRef
Hepatocyte Kctd17 Inhibition Ameliorates Glucose Intolerance and Hepatic Steatosis Caused by Obesity-induced Chrebp Stabilization Ah-Reum Oh, Yelin Jeong, Junjie Yu, Dao Thi Minh Tam, Jin Ku Kang, Young Hoon Jung, Seung-Soon Im, Sang Bae Lee, Dongryeol Ryu, Utpal B. Pajvani, KyeongJin Kim Gastroenterology.2023; 164(3): 439. CrossRef
Regulation of Liver Glucose and Lipid Metabolism by Transcriptional Factors and Coactivators Balamurugan Ramatchandirin, Alexia Pearah, Ling He Life.2023; 13(2): 515. CrossRef
Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXR Jingyi Guo, Shangyi Huang, Qincheng Yi, Naihua Liu, Tianqi Cui, Siwei Duan, Jiabing Chen, Jiayu Li, Jun Li, Lei Wang, Yong Gao, Guangning Nie ACS Omega.2023; 8(29): 26158. CrossRef
MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis Nancy de los Ángeles Segura-Azuara, Carlos Daniel Varela-Chinchilla, Plinio A. Trinidad-Calderón Frontiers in Medicine.2022;[Epub] CrossRef
Protective Effect and Mechanism of Plant-Based Monoterpenoids in Non-alcoholic Fatty Liver Diseases Wenji Zhang, Hui Lin, Wenli Cheng, Zhenrui Huang, Wenjuan Zhang Journal of Agricultural and Food Chemistry.2022; 70(16): 4839. CrossRef
Liposomal Form of 2,4-Dinitrophenol Lipophilic Derivatives as a Promising Therapeutic Agent for ATP Synthesis Inhibition Kseniya Yu. Vlasova, Petr Ostroverkhov, Daria Vedenyapina, Tamara Yakimova, Alla Trusova, Galina Yurievna Lomakina, Stepan Sergeevich Vodopyanov, Mikhail Grin, Natalia Klyachko, Vladimir Chekhonin, Maxim Abakumov Nanomaterials.2022; 12(13): 2162. CrossRef
Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population Huiyul Park, Eileen L. Yoon, Mimi Kim, Jonghyun Lee, Seon Cho, Dae Won Jun, Eun-Hee Nah Frontiers in Medicine.2022;[Epub] CrossRef
Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan Clinical and Molecular Hepatology.2021; 27(1): 83. CrossRef
Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease Jae Seung Lee, Dong Hyun Sinn, Soo Young Park, Hye Jung Shin, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Joo Hyun Oh, Jung Il Lee, Seung Up Kim Cancers.2021; 13(18): 4567. CrossRef
Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease Ho Soo Chun, Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Cachexia, Sarcopenia and Muscle.2021; 12(5): 1168. CrossRef
Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Tracey G. Simon, Andrew T. Chan, Seong Gyu Hwang Scientific Reports.2021;[Epub] CrossRef
BTT‐105 ameliorates hepatic fibrosis in non‐alcoholic fatty liver animal model Hye Young Kim, Sang Bong Ahn, Jeong‐Min Hong, Ju Hee Oh, Waqar Khalid Saeed, Gyu Sik Kim, Hyun Kim, Jong Koo Kang, Sukmo Kang, Dae Won Jun The FASEB Journal.2021;[Epub] CrossRef
Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease Dong Hyun Sinn, Danbee Kang, Soo Jin Cho, Seung Woon Paik, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak European Journal of Gastroenterology & Hepatology.2021; 33(1S): e529. CrossRef
Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development Komal Thapa, Ajmer Singh Grewal, Neha Kanojia, Lata Rani, Neelam Sharma, Sukhbir Singh Current Drug Discovery Technologies.2021; 18(3): 333. CrossRef
Non‐alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study Dong Hyun Sinn, Danbee Kang, Yoosoo Chang, Seungho Ryu, Soo Jin Cho, Seung Woon Paik, Young Bin Song, Roberto Pastor‐Barriuso, Eliseo Guallar, Juhee Cho, Geum‐Youn Gwak Journal of Gastroenterology and Hepatology.2020; 35(5): 833. CrossRef
Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study Jeong-Ju Yoo, Yang Jae Yoo, Woo Ram Moon, Seung Up Kim, Soung Won Jeong, Ha Na Park, Min Gyu Park, Jae Young Jang, Su Yeon Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Sang Gyune Kim, Young Seok Kim, Ji Hoon Kim, Jong The Korean Journal of Internal Medicine.2020; 35(6): 1346. CrossRef
Non-invasive monitoring of hepatic steatosis via acoustic structure quantification of ultrasonography with MR spectroscopy as the reference standard Dong Ho Lee, Jae Young Lee, Min Sun Park, Joon Koo Han Ultrasonography.2020; 39(1): 70. CrossRef
Weight Change and Development of Subclinical Carotid Atherosclerosis Among Metabolically Healthy Adults: A Cohort Study Dong Hyun Sinn, Danbee Kang, Soo Jin Cho, Yoosoo Chang, Seungho Ryu, Young Bin Song, Seung Woon Paik, Yun Soo Hong, Di Zhao, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak The Journal of Clinical Endocrinology & Metabolism.2020; 105(3): e410. CrossRef
Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk Eugene Han, Yong-ho Lee, Young Dae Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Kwang-Hyub Han, Hyo Suk Nam, Ji Hoe Heo, Seung Up Kim American Journal of Gastroenterology.2020; 115(4): 584. CrossRef
Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis? Hyuk Soo Eun Clinical and Molecular Hepatology.2020; 26(2): 236. CrossRef
Expression of the Long Noncoding RNA GAS5 Correlates with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Man-Hoon Han, Jee Hyun Lee, Gyeonghwa Kim, Eunhye Lee, Yu Rim Lee, Se Young Jang, Hye Won Lee, Jae Min Chun, Young Seok Han, Jun Sik Yoon, Min Kyu Kang, Won Kee Lee, Young Oh Kweon, Won Young Tak, Soo Young Park, Jung Gil Park, Keun Hur Genes.2020; 11(5): 545. CrossRef
Plasma Long Noncoding RNA LeXis is a Potential Diagnostic Marker for Non-Alcoholic Steatohepatitis Jung Gil Park, Gyeonghwa Kim, Se Young Jang, Yu Rim Lee, Eunhye Lee, Hye Won Lee, Man-Hoon Han, Jae Min Chun, Young Seok Han, Jun Sik Yoon, Min Kyu Kang, Young Oh Kweon, Won Young Tak, Soo Young Park, Keun Hur Life.2020; 10(10): 230. CrossRef
Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang Digestive Diseases.2020; 38(6): 507. CrossRef
Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease Min Cheol Kim, Jung Gil Park, Byung Ik Jang, Heon Ju Lee, Won Kee Lee Medicine.2019; 98(6): e14139. CrossRef
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology In Cheol Yoon, Jong Ryeol Eun Yeungnam University Journal of Medicine.2019; 36(2): 67. CrossRef
The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease Young-Kyu Kim, Oh-Sung Kwon, Kyu Hee Her Medicine.2019; 98(27): e16018. CrossRef
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B? Jung Hwan Yu, Jin-Woo Lee Clinical and Molecular Hepatology.2019; 25(3): 280. CrossRef
Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery Young-Sun Lee, Ha Seok Lee, Sung Won Chang, Chan Uk Lee, Jung Sun Kim, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Chang Hee Lee, Sang Uk Woo, Jae Hong Seo, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun Medicine.2019; 98(39): e17277. CrossRef
ASPECTS OF IMMUNOLOGICAL STATUS AND CARBON METABOLISM IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN CORRELATION WITH ITS FIBROUS TRANSFORMATION
Y. M. Stepanov, V. I. Didenko, I. S. Konenko, O. M. Tatarchuk, O. P. Petishko Bulletin of Problems Biology and Medicine.2019; 3(152): 196. CrossRef
Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease Do Seon Song, U Im Chang, Sung-Goo Kang, Sang-Wook Song, Jin Mo Yang Gut and Liver.2019; 13(6): 658. CrossRef
Normal serum alanine aminotransferase and non-alcoholic fatty liver disease among Korean adolescents: a cross-sectional study using data from KNHANES 2010–2015 Yunkoo Kang, Sowon Park, Seung Kim, Hong Koh BMC Pediatrics.2018;[Epub] CrossRef
Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD) Zahra Dehnavi, Farkhonde Razmpour, Mahmoud Belghaisi Naseri, Mohsen Nematy, Seyed Ali Alamdaran, Hassan Ali Vatanparast, Mohsen Azimi Nezhad, Bita Abbasi, Azita Ganji Hepatitis Monthly.2018;[Epub] CrossRef
CGplus, a standardized herbal composition ameliorates non-alcoholic steatohepatitis in a tunicamycin-induced mouse model Myong-Min Lee, Hyeong-Geug Kim, Sung-Bae Lee, Jin-Seok Lee, Won-Yong Kim, Seung-Hoon Choi, Sam-Keun Lee, Chang-Kyu Byun, Pung-Mi Hyun, Chang-Gue Son Phytomedicine.2018; 41: 24. CrossRef
Neue und bewährte Therapieansätze bei NASH Peter C. Konturek MMW - Fortschritte der Medizin.2018; 160(5): 50. CrossRef
Estimated Prevalence of Adolescents with Nonalcoholic Fatty Liver Disease in Korea Yunkoo Kang, Sowon Park, Seung Kim, Hong Koh Journal of Korean Medical Science.2018;[Epub] CrossRef
Recent advances in understanding and managing non-alcoholic fatty liver disease Somaya Albhaisi, Arun Sanyal F1000Research.2018; 7: 720. CrossRef
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis Stephen A. Harrison, Manal F. Abdelmalek, Stephen Caldwell, Mitchell L. Shiffman, Anna Mae Diehl, Reem Ghalib, Eric J. Lawitz, Don C. Rockey, Raul Aguilar Schall, Catherine Jia, Bryan J. McColgan, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Gastroenterology.2018; 155(4): 1140. CrossRef
Serological biomarkers associate ultrasound characteristics of steatohepatitis in mice with liver cancer Guozhen Cui, Robert C Martin, Xingkai Liu, Qianqian Zheng, Harshul Pandit, Ping Zhang, Wei Li, Yan Li Nutrition & Metabolism.2018;[Epub] CrossRef
Serotonin signals through a gut-liver axis to regulate hepatic steatosis Wonsuk Choi, Jun Namkung, Inseon Hwang, Hyeongseok Kim, Ajin Lim, Hye Jung Park, Hye Won Lee, Kwang-Hyub Han, Seongyeol Park, Ji-Seon Jeong, Geul Bang, Young Hwan Kim, Vijay K. Yadav, Gerard Karsenty, Young Seok Ju, Chan Choi, Jae Myoung Suh, Jun Yong Par Nature Communications.2018;[Epub] CrossRef
Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease Waqar Khalid Saeed, Dae Won Jun, Kiseok Jang, Sang Bong Ahn, Ju Hee Oh, Yeon Ji Chae, Jai Sun Lee, Hyeon Tae Kang World Journal of Gastroenterology.2018; 24(48): 5477. CrossRef
Changes in the Structure of the Liver during Obesity (Literature Review) V. I. Prymachenko Ukraïnsʹkij žurnal medicini, bìologìï ta sportu.2018; 4(2): 45. CrossRef
Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage Alessia Di Costanzo, Laura D'Erasmo, Licia Polimeni, Francesco Baratta, Paola Coletta, Michele Di Martino, Lorenzo Loffredo, Ludovica Perri, Fabrizio Ceci, Anna Montali, Gabriella Girelli, Bruna De Masi, Antonio Angeloni, Carlo Catalano, Marianna Maranghi Atherosclerosis.2017; 257: 232. CrossRef
Salvia-Nelumbinis Naturalis Formula Improved Inflammation in LPS Stressed Macrophages via Upregulating MicroRNA-152 Zansong Ma, Xiangbing Shu, Jie Huang, Haiyan Zhang, Zhen Xiao, Li Zhang Mediators of Inflammation.2017; 2017: 1. CrossRef
Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota Michael Doulberis, Georgios Kotronis, Dimitra Gialamprinou, Jannis Kountouras, Panagiotis Katsinelos Metabolism.2017; 71: 182. CrossRef
Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Joon Kim, Kwang-Hyub Han Digestive Diseases and Sciences.2017; 62(8): 2150. CrossRef
Non-alcoholic Fatty Liver Disease: A Clinical Update Joseph M Pappachan, Shithu Babu, Babu Krishnan, Nishal C Ravindran Journal of Clinical and Translational Hepatology.2017; XX(XX): XX. CrossRef
A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis Baek Gyu Jun, Won Young Park, Eui Ju Park, Jae Young Jang, Soung Won Jeong, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, So Young Jin, Suyeon Park, Seung Up Kim PLOS ONE.2017; 12(8): e0182784. CrossRef
The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter Hye Won Lee, Kwang Joon Kim, Kyu Sik Jung, Young Eun Chon, Ji Hye Huh, Kyeong Hye Park, Jae Bock Chung, Chang Oh Kim, Kwang-Hyub Han, Jun Yong Park, Han-Chieh Lin PLOS ONE.2017; 12(10): e0187066. CrossRef
Serum fetuin A level is associated with nonalcoholic fatty liver disease in Chinese population Zhengsen Cui, Rong Xuan, Yunmei Yang Oncotarget.2017; 8(63): 107149. CrossRef
First
Prev
